The 13th Australian Peptide Conference, which will be held at the Oaks Resort, Port Douglas, Queensland, Australia, from the 8th to 13th September 2019. The theme of the conference is “Peptides - Turning the Tide”. The conference organising committee is currently assembling an exciting scientific program containing a mix of peptide synthesis and discovery, engineering, characterisation, structure-based drug design, therapeutics development and technological advances in the field.
More information: check link here
Angiotensin IV (AT4) is a hexapeptide (Val-Tyr-Ile-His-Pro-Phe) that has a wide range of activities in the central nervous system. There is evidence that the AT4 receptor (AT4R)is insulin-regulated aminopeptidase (IRAP).There is also evidence that AT4 interacts with the HGF system through the c-Met receptor. Synthetic small molecule analogues of AT4 with the ability to penetrate through blood brain barrier have been developed.
Diazepam binding inhibitor (DBI) is a 9-kD polypeptide that was first isolated in 1983 from rat brain by monitoring its ability to displace diazepam from the benzodiazepine (BZD) recognition site located on the extracellular domain of the type A receptor for gamma-aminobutyric acid (GABAA receptor) and from the mitochondrial BZD receptor (MBR) located on the outer mitochondrial membrane. In brain, DBI and its two major processing products [DBI 33-50, or octadecaneuropeptide (ODN) and DBI 17-50, or triakontatetraneuropeptide (TTN)] are unevenly distributed in neurons, with the highest concentrations of DBI (10 to 50 microMs) being present in the hypothalamus, amygdala, cerebellum, and discrete areas of the thalamus, hippocampus, and cortex.
Alzheimer's disease (AD) Alzheimer's disease (AD) has become a major world-wide health problem with ever rising costs associated with the treatment and care of afflicted individuals. As life expectancy has increased the occurrence of dementia has also increased. Hypertension during middle adulthood is correlated with a significantly elevated risk of cognitive impairment later in life. Treatment with antihypertensive drugs, particularly angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), has been reported to reduce the likelihood and slow the progression of AD.
